WAC 296-62-07339
Appendix C -- Medical surveillance
guidelines for acrylonitrile. (1) Route of entry.
(a) Inhalation;
(b) Skin absorption;
(c) Ingestion.
(2) Toxicology.
(a) Acrylonitrile vapor is an asphyxiant due to
inhibitory action on metabolic enzyme systems. Animals
exposed to 75 or 100 ppm for seven hours have shown signs of
anoxia; in some animals which died at the higher level,
cyanomethemoglobin was found in the blood. Two human
fatalities from accidental poisoning have been reported; one
was caused by inhalation of an unknown concentration of the
vapor, and the other was thought to be caused by skin
absorption or inhalation. Most cases of intoxication from
industrial exposure have been mild, with rapid onset of eye
irritation, headache, sneezing, and nausea. Weakness,
lightheadedness, and vomiting may also occur. Exposure to
high concentrations may produce profound weakness, asphyxia,
and death. The vapor is a severe eye irritant. Prolonged
skin contract [contact] with the liquid may result in absorption with systemic
effects, and in the formation of large blisters after a latent
period of several hours. Although there is usually little or
no pain or inflammation, the affected skin resembles a
second-degree thermal burn. Solutions spilled on exposed
skin, or on areas covered only by a light layer of clothing,
evaporate rapidly, leaving no irritation, or, at the most,
mild transient redness. Repeated spills on exposed skin may
result in dermatitis due to solvent effects.
(b) Results after one year of a planned two-year animal
study on the effects of exposure to acrylonitrile have
indicated that rats ingesting as little as 35 ppm in their
drinking water develop tumors of the central nervous system. The interim results of this study have been supported by a
similar study being conducted by the same laboratory,
involving exposure of rats by inhalation of acrylonitrile
vapor, which has shown similar types of tumors in animals
exposed to 80 ppm.
(c) In addition, the preliminary results of an
epidemiological study being performed by duPont on a cohort of
workers in their Camden, S.C. acrylic fiber plant indicate a
statistically significant increase in the incidence of colon
and lung cancers among employees exposed to acrylonitrile.
(3) Signs and symptoms of acute overexposure. Asphyxia
and death can occur from exposure to high concentrations of
acrylonitrile. Symptoms of overexposure include eye
irritation, headache, sneezing, nausea and vomiting, weakness,
and light-headedness. Prolonged skin contact can cause
blisters on the skin with appearance of a second-degree burn,
but with little or no pain. Repeated skin contact may produce
scaling dermatitis.
(4) Treatment of acute overexposure. Remove employee
from exposure. Immediately flush eyes with water and wash
skin with soap or mild detergent and water. If AN has been
swallowed, and person is conscious, induce vomiting. Give
artificial respiration if indicated. More severe cases, such
as those associated with loss of consciousness, may be treated
by the intravenous administration of sodium nitrite, followed
by sodium thiosulfate, although this is not as effective for
acrylonitrile poisoning as for inorganic cyanide poisoning.
(5) Surveillance and preventive considerations.
(a) As noted above, exposure to acrylonitrile has been
linked to increased incidence of cancers of the colon and lung
in employees of the duPont acrylic fiber plant in Camden, S.C.
In addition, the animal testing of acrylonitrile has resulted
in the development of cancers of the central nervous system in
rats exposed by either inhalation or ingestion. The physician
should be aware of the findings of these studies in evaluating
the health of employees exposed to acrylonitrile.
(b) Most reported acute effects of occupational exposure
to acrylonitrile are due to its ability to cause tissue anoxia
and asphyxia. The effects are similar to those caused by
hydrogen cyanide. Liquid acrylonitrile can be absorbed
through the skin upon prolonged contact. The liquid readily
penetrates leather, and will produce burns of the feet if
footwear contaminated with acrylonitrile is not removed.
(c) It is important for the physician to become familiar
with the operating conditions in which exposure to
acrylonitrile may occur. Those employees with skin diseases
may not tolerate the wearing of whatever protective clothing
may be necessary to protect them from exposure. In addition,
those with chronic respiratory disease may not tolerate the
wearing of negative-pressure respirators.
(d) Surveillance and screening. Medical histories and
laboratory examinations are required for each employee subject
to exposure to acrylonitrile above the action level. The
employer must screen employees for history of certain medical
conditions which might place the employee at increased risk
from exposure.
(i) Central nervous system dysfunction. Acute effects of
exposure to acrylonitrile generally involve the central
nervous system. Symptoms of acrylonitrile exposure include
headache, nausea, dizziness, and general weakness. The animal
studies cited above suggest possible carcinogenic effects of
acrylonitrile on the central nervous system, since rats
exposed by either inhalation or ingestion have developed
similar CNS tumors.
(ii) Respiratory disease. The duPont data indicate an
increased risk of lung cancer among employees exposed to
acrylonitrile.
(iii) Gastrointestinal disease. The duPont data indicate
an increased risk of cancer of the colon among employees
exposed to acrylonitrile. In addition, the animal studies
show possible tumor production in the stomachs of the rats in
the ingestion study.
(iv) Skin disease. Acrylonitrile can cause skin burns
when prolonged skin contact with the liquid occurs. In
addition, repeated skin contact with the liquid can cause
dermatitis.
(e) General. The purpose of the medical procedures
outlined in the standard is to establish a baseline for future
health monitoring. Persons unusually susceptible to the
effects of anoxia or those with anemia would be expected to be
at increased risk. In addition to emphasis on the CNS,
respiratory and gastro-intestinal systems, the cardiovascular
system, liver, and kidney function should also be stressed.
[Statutory Authority: Chapter 49.17 RCW. 88-11-021 (Order
88-04), § 296-62-07339, filed 5/11/88.]